AP ISMPP U: Optimizing and Enhancing Publications for Virtual Congresses (January 2021)
At
the end of this session, attendees should:
- Be familiar with the evolution of the GPP guidelines and the process used to try and ensure their broad and relevant applicability
- Understand the updated GPP3 guidance on authorship requirements and recommendations for common authorship issues
- Gain an understanding of the rationale for the new "What Studies to Publish" section
- Know what type(s) of clinical studies should be published, where they should be published and when
- Be familiar with the pharmaceutical association joint position statement
- Be able to appropriately manage the "difficult to publish" studies
- Understand how "disclosure" is a less ambiguous term than "conflict of interest" (or "potential of conflict of interest") and can promote greater transparency
- Understand how GPP3 allows for compensation at fair market value for activities related to medical publishing